UNSPSC 51384520: Zaltoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H14O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H8635NG3PY, chemically known as 10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid but generally known as zaltoprofen, which bears US NIH Compound Identifier 5720. European Medicines Agency schedules Zaltoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00135MIG.

UNSPSC 51384520 Zaltoprofen is a Commodity code that nominally describes a specific nonsteroidal anti-inflammatory drug, but recent state and local solicitations tagged with this code show no procurement activity for zaltoprofen itself. Instead, the tagged opportunities involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical supply agreements—none of which align with the code's stated scope. The mismatch between the code definition and actual solicitation content suggests either a data-entry error in the tagging or that state procurement systems are using this code as a catch-all for pharmaceutical purchasing without semantic precision.

Recent opportunities in the pharmaceutical space do not reflect demand specifically for zaltoprofen. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking naloxone and drug deactivation systems with quarterly deliveries, while the Texas Health and Human Services Commission posted an RFI in April 2026 to explore direct-to-manufacturer prescription models outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted heavily on price competitiveness (75 percent). These solicitations span state health departments, county community health programs, and cooperative purchasing vehicles, but none specifically target zaltoprofen as a line item. Without evidence of recent state or local demand for zaltoprofen under this code, the code shows little relevant procurement activity.